SBIR Phase I: Development and assessment of a diagnostic platform for rapid identification of COVID-19 patients without using custom reagents

Information

  • NSF Award
  • 2029745
Owner
  • Award Id
    2029745
  • Award Effective Date
    7/1/2020 - 4 years ago
  • Award Expiration Date
    12/31/2020 - 3 years ago
  • Award Amount
    $ 256,000.00
  • Award Instrument
    Standard Grant

SBIR Phase I: Development and assessment of a diagnostic platform for rapid identification of COVID-19 patients without using custom reagents

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to deploy a diagnostic to rapidly and inexpensively detect COVID-19 infections. Beyond the short-term goal of identifying COVID-19 patients, the technology will lend strong support for real-time infection tracking nationally. The same hardware components of the diagnostic can be used to identify a wide variety of pathogens without custom reagents. The system will work with a cloud-based database and monitoring system to rapidly identify hotspots of increased pathogen activity, enabling faster response to new pathogens since no hardware-related development, manufacturing, and distribution are needed. Once a new pathogen?s fingerprint is obtained, it can be easily distributed to deployed instruments to enable immediately tracking of the new pathogen. <br/><br/>This Small Business Innovation Research (SBIR) Phase I project aims to develop a rapid diagnostic capable of detecting SARS-nCoV2 directly from sample matrices without the use of custom reagents (like DNA) or a cold supply chain. The approach isolates intact virus directly from the specimen with the help of a disposable cartridge and a syringe pump. The isolated virus is then identified using Fourier-Transform Infrared Spectrometry (FTIR). The proposed work leverages the differential response to mechanical stress between the virus and the components of a sample matrix. This differential response is used to selectively lyse only the sample matrix components, not the virus. The debris is subsequently separated from the virus by size-based separation methods such as filtration, enabling rapid isolation of a broad range of pathogens directly from the sample. FTIR is used to identify the isolated virus since pathogens exhibit unique spectral fingerprints in the infrared region. The proposed Phase I effort will develop the protocol for isolating and identifying intact virus and will demonstrate the performance with nasopharyngeal swab samples. The results will be compared against results from RT-PCR methods to assess comparability.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

  • Program Officer
    Henry Ahn
  • Min Amd Letter Date
    7/2/2020 - 4 years ago
  • Max Amd Letter Date
    7/2/2020 - 4 years ago
  • ARRA Amount

Institutions

  • Name
    3I Diagnostics, Inc.
  • City
    Germantown
  • State
    MD
  • Country
    United States
  • Address
    20271 Goldenrod Lane
  • Postal Code
    208764064
  • Phone Number
    3015156380

Investigators

  • First Name
    Rajesh
  • Last Name
    Krishnamurthy
  • Email Address
    rk@3idx.com
  • Start Date
    7/2/2020 12:00:00 AM

Program Element

  • Text
    SBIR Phase I
  • Code
    5371

Program Reference

  • Text
    COVID-19 Research
  • Text
    Biotechnology
  • Code
    8038